Heart-liver co-management: epidemiology, mechanisms, and novel therapeutic approaches for metabolic dysfunction-associated steatotic liver disease and coronary artery disease
Frontiers in Cardiovascular Medicine · 27.07.2026 · 13
DOI: 10.3389/fcvm.2026.1843719 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 27.07.2026. Verfasst von Sirui Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China. Die Arbeit nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) and coronary artery disease (CAD) are interconnected global health epidemics that substantially contribute to worldwide morbidity and mortality. We aimed to provide a systematic overview of the epidemiological links and shared pathophysiological mechanisms between MASLD and CAD, evaluate emerging therapeutic strategies with dual benefits, and advocate for an integrated “dual-heart-liver” management model.
Methods
We synthesize current evidence to examine the epidemiological link between MASLD and CAD and their shared pathophysiological mechanisms, including endothelial dysfunction, chronic inflammation, metabolic imbalance, insulin resistance, and genetic associations. We also discuss the roles of genetic predisposition, lifestyle modification, and combination therapies in improving patient outcomes. Furthermore, recent advances in pharmacotherapy—such as resmetirom, GLP-1 receptor agonists, SGLT2 inhibitors, FGF21 analogues, PCSK9 inhibitors, and PPAR agonists—are evaluated for their dual benefits on hepatic and cardiovascular health Results Epidemiological studies confirm a bidirectional, mutually reinforcing relationship between MASLD and CAD, which are linked through multiple pathophysiological pathways. In terms of treatment, novel pharmacotherapies—such as resmetirom, GLP-1 receptor agonists, SGLT2 inhibitors, FGF21 analogues, PCSK9 inhibitors, and PPAR agonists—show considerable potential for conferring concurrent hepatic and cardiovascular benefits. Furthermore, combination therapies also play important roles in optimizing patient outcomes.
Conclusions
This review calls for a paradigm shift toward an integrated “dual-heart-liver” management model, emphasizing the need for systematic cardiovascular risk assessment in MASLD patients and the implementation of collaborative care strategies to improve long-term prognosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.
- Department of Cardiology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Zitieren
APA
Zhu, S., Yang, F., Lu, H., Jiang, J., & He, W. (2026). Heart-liver co-management: epidemiology, mechanisms, and novel therapeutic approaches for metabolic dysfunction-associated steatotic liver disease and coronary artery disease. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1843719
Vancouver
Zhu S, Yang F, Lu H, Jiang J, He W. Heart-liver co-management: epidemiology, mechanisms, and novel therapeutic approaches for metabolic dysfunction-associated steatotic liver disease and coronary artery disease. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1843719
BibTeX
@article{Zhu2026,
author = {Zhu, Sirui and Yang, Fangkun and Lu, Haoxuan and Jiang, Jun and He, Wenming},
title = {Heart-liver co-management: epidemiology, mechanisms, and novel therapeutic approaches for metabolic dysfunction-associated steatotic liver disease and coronary artery disease},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1843719}
}
EUVIMED